Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8909426 | 1.00 | LMNA (0.52) | LMNACYP3A4MEN1ALOX15KMT2A | |
| SCHEMBL17885433 | 1.00 | LMNA (0.52) | LMNACYP3A4MEN1ALOX15KMT2A | |
| SCHEMBL15822080 | 1.00 | LMNA (0.52) | LMNACYP3A4MEN1ALOX15KMT2A | |
| SCHEMBL15825970 | 1.00 | LMNA (0.52) | LMNACYP3A4MEN1ALOX15KMT2A | |
| SCHEMBL17268254 | 1.00 | LMNA (0.52) | LMNACYP3A4MEN1ALOX15KMT2A | |
| SCHEMBL18697210 | 0.83 | LMNA (0.52) | LMNACYP3A4MEN1ALOX15KMT2A | |
| SCHEMBL21180973 | 0.83 | LMNA (0.52) | LMNACYP3A4MEN1ALOX15KMT2A | |
| SCHEMBL10834300 | 0.83 | LMNA (0.52) | LMNACYP3A4MEN1ALOX15KMT2A | |
| SCHEMBL17885434 | 0.83 | LMNA (0.52) | LMNACYP3A4MEN1ALOX15KMT2A | |
| SCHEMBL2400702 | 0.81 | TSHR (0.41) | LMNACYP3A4MEN1ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935177-B1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE | DSM IP ASSETS BV (NL) | 2019-07-24 | — | — | EP | disclosed |
| EP-2935189-B1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINING ASYMMETRIC HYDROGENATION AND ISOMERIZATION | DSM IP ASSETS BV (NL) | 2019-06-12 | — | — | EP | disclosed |
| EP-2935233-B1 | PROCESS OF ASYMMETRIC HYDROGENATION OF KETALS AND ACETALS | DSM IP ASSETS BV (NL) | 2019-01-30 | — | — | EP | disclosed |
| EP-2935188-B1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINED ASYMMETRIC HYDROGENATIONS | DSM IP ASSETS BV (NL) | 2018-08-01 | — | — | EP | disclosed |
| CN-104918909-B | Specific product is quantitatively obtained by the asymmetric hydrogenation of combination using the mixture of E/Z isomers | 帝斯曼知识产权资产管理有限公司 | 2018-05-11 | — | — | CN | disclosed |
| CN-104854069-B | (6R,10R) -6,10, 14-trimethylpentadecan-2-one prepared from 6, 10-dimethylundec-5-en-2-one or 6, 10-dimethylundec-5, 9-dien-2-one | 帝斯曼知识产权资产管理有限公司 | 2017-06-20 | — | — | CN | disclosed |
| US-9573872-B2 | Using mixtures of E/Z isomers to obtain quantitatively specific products by combining asymmetric hydrogenation and isomerization | DSM IP ASSETS B.V. (NL) | 2017-02-21 | — | — | US | disclosed |
| US-9561989-B2 | Process of asymmetric hydrogenation of ketals and acetals | DSM IP ASSETS B.V. (NL) | 2017-02-07 | — | — | US | disclosed |
| US-9458076-B2 | Using mixtures of E/Z isomers to obtain quantitatively specific products by combined asymmetric hydrogenations | DSM IP ASSETS B.V. (NL) | 2016-10-04 | — | — | US | disclosed |
| US-9452961-B2 | (6R,10R)-6,10,14-trimetylpentadecan-2-one prepared from 6,10-dimetylundec-5-en-2-one or 6,10-dimetylundeca-5,9-dien-2-one | DSM IP ASSETS B.V. (NL) | 2016-09-27 | — | — | US | disclosed |
| US-20150329457-A1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE | DSM IP ASSETS B.V. (NL) | 2015-11-19 | — | — | US | disclosed |
| US-20150329457-A1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE | DSM IP ASSETS B.V. (NL) | 2015-11-19 | — | — | US | disclosed |
| US-20150321986-A1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINED ASYMMETRIC HYDROGENATIONS | DSM IP ASSETS B.V. (NL) | 2015-11-12 | — | — | US | disclosed |
| EP-2935233-A1 | PROCESS OF ASYMMETRIC HYDROGENATION OF KETALS AND ACETALS | DSM IP Assets B.V. (NL) | 2015-10-28 | — | — | EP | disclosed |
| CN-104918909-A | Using mixtures of E/Z isomers to obtain quantitatively specific products by combined asymmetric hydrogenations | DSM IP ASSETS BV | 2015-09-16 | — | — | CN | disclosed |
| CN-104884446-A | Asymmetric Hydrogenation of Ketals and Acetals | DSM IP ASSETS BV | 2015-09-02 | — | — | CN | disclosed |
| CN-104884420-A | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINING ASYMMETRIC HYDROGENATION AND ISOMERIZATION | DSM IP ASSETS BV | 2015-09-02 | — | — | CN | disclosed |
| CN-104854069-A | (6R,10R) -6,10, 14-trimethylpentadecan-2-one prepared from 6, 10-dimethylundec-5-en-2-one or 6, 10-dimethylundec-5, 9-dien-2-one | DSM IP ASSETS BV | 2015-08-19 | — | — | CN | disclosed |
| WO-2014096096-A1 | PROCESS OF ASYMMETRIC HYDROGENATION OF KETALS AND ACETALS | DSM IP ASSETS B.V. (NL) | 2014-06-26 | — | — | WO | disclosed |
| US-5600015-A | USING RUTHENIUM COMPLEX OF OPTICALLY ACTIVE ATROPISOMERIC DIPHOSPHINE LIGAND AS HYDROGENATION CATALYST | HOFFMANN-LA ROCHE INC. (US) | 1997-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150321986-A1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINED ASYMMETRIC HYDROGENATIONS | EPHX2, HBZ, ELOVL5 | LMNA 681/4885CYP3A4 247/4885MEN1 1465/4885 |
| US-20150329457-A1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE | PDE12, CYP2D6, PDE9A | LMNA 1447/4885CYP3A4 111/4885MEN1 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.